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Asymmetric methodologies are very important as they allow chemists to produce 
significant quantities of complex chiral molecules as enantiopure or enantioenriched 
compounds. The Petersen group has previously developed chiral Brønsted acid 
catalyzed desymmetrization reactions for the asymmetric synthesis of lactones. The 
work described in this thesis provides an application for this methodology to the 
synthesis of enantioenriched spirocycles, motifs present in many biologically active 
molecules. This synthesis is performed in the presence of TRIP, a chiral BINOL-derived 
phosphoric acid catalyst, which guides the cyclization of symmetric prochiral 
intermediates. The research in this thesis describes the synthesis of two enantioenriched 
spirocycles, one of which posed many synthetic challenges. Even though the results 
were nonconclusive, more synthetic work towards the understanding of the mechanistic 
pathway is also introduced. Therefore, the work described herein not only contributes to 
the substrate scope of the reaction that was developed, but also provides discussion to 
the challenges faced during the synthesis of these compounds. 
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CHAPTER I 
INTRODUCTION 
 
 
1.1 Definition of Chirality and Types of Chiral Molecules 
 The spatial orientation of atoms can sometimes create molecules that are mirror 
images of each other but cannot be superimposed (Figure 1). These types of 
compounds are chiral and are called enantiomers or optical isomers. Optical isomerism 
is attributed to the enantiomers’ ability to rotate plane-polarized light in opposite 
directions thanks to their three-dimensional shape. Unlike other types of isomers, these 
seemingly identical molecules cannot be obtained by simple bond rotations. The unique 
3D structure resulting from this type of isomerism is usually due to the presence of a 
chiral center, or stereocenter (noted as X in Figure 1). A stereocenter can be a sp3-
hybridized atom bound to four different atoms that give the molecule its stereospecificity.  
 
       
Figure 1. Enantiomers as Non-superimposable Mirror Images 
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Chirality, however, can also be observed in molecules that don’t have a stereocenter but 
are trapped in a certain conformation. Most of these molecules exhibit an axis of chirality 
and rotation around that axis is not viable. Examples of such chiral molecules include 
allenes 1 where rotation is not possible because it requires the destruction of π bonds or 
binapthyls (2, 3) where the rotation is restricted because of steric hindrance (Figure 2). 
 
 
Figure 2. Examples of Molecules with Axial Chirality  
 
 
1.2 Absolute Configuration and Chiral Environments 
To distinguish enantiomers from each other, chemists have been using the 
Cahn−Ingold−Prelog Sequence Rules since 1956 when they were first introduced.[1] 
These rules are used to assign a name to the absolute configuration of the molecules 
and help differentiate one enantiomer from the other by naming one as (R) and the other 
as (S). When the absolute configuration (absolute spatial orientation of the atoms) is 
determined experimentally, the CIP rules can be used to assign a name to that specific 
enantiomer. X-Ray crystallography is one of the most commonly used techniques to 
determine the absolute configuration of compounds. Other techniques that can provide 
insight on the spatial orientation of atoms include the Mosher ester analysis,[2] chiral 
3 
liquid crystallography,[3] circular dichroism (CD), optical rotatory dispersion (ORD), 
vibrational circular di-chroism (VCD),[3] or Raman optical activity (ROA).[4] 
 This intrinsic three-dimensional shape is a crucial component of chiral 
compounds as it dictates how they interact with other chiral molecules or chiral 
environments. Proteins provide an important chiral environment and examples of these 
interactions include protein-protein, receptor-ligand, or enzyme-substrate interactions.[5] 
These macromolecules have an essential quaternary structure that is created during 
protein folding and is aided by intramolecular and intermolecular bonds. The quaternary 
protein structure can interact with the chiral molecules that surround them in a very 
specific way (usually understood through a lock and key model- Figure 3). 
 
 
Figure 3. Enantiomers and Their Binding Specificity 
 
 
1.3 Importance of Chirality and the Need for Enantiopure APIs  
 The molecules that bind to the quaternary structure of the proteins can often 
affect the macromolecule by changing its conformation and eventually, through a series 
of chain reactions, cause desired or undesired effects in living organisms. Many of the 
molecules or drugs that are intentionally prescribed to patients to achieve a certain 
4 
outcome are chiral or have chiral active ingredients. More than half of all marketed drugs 
are chiral and almost 9 out of the top 10 drugs have chiral active ingredients.[6] Since 
1992 the United States Food and Drug Administration has implemented rules that shift 
the focus towards single enantiomers and the establishment of the absolute 
stereochemistry early in drug development.[5] After the change in regulations, the 
worldwide sales of single enantiomer drugs in 2000 were reported as growing at 13% 
annually and totally $133 billion.[5] This shift of focus towards enantiopure or single 
enantiomeric drugs is closely related to the undesired effects that have been observed 
over the years when prescribing racemic mixtures (50:50 mixtures of both enantiomers) 
to patients. Two of many examples of how drastically different the effects of the two 
enantiomers can be include Methamphetamine and Naproxen (Figure 4). (R)- 
methamphetamine 5 is an over-the-counter nasal decongestant, while the (S)- 
methamphetamine 4 is the well-known addictive stimulant drug.[7] (S)-naproxen 6, on the 
other hand, is used as a pain reliever, but (R)-naproxen 7 is found to cause 
hepatotoxicity.[8] To avoid any unpredicted side effects, chemists have shifted their focus 
towards obtaining enantiopure chiral active pharmaceutical ingredients (APIs).  
 
 
Figure 4. Examples of Enantiomers with Undesired Side Effects 
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1.4 Methods of Separating Enantiomers 
 Obtaining enantiopure (100:0 enantiomeric ratio) or enantioenriched (> 50:50 
enantiomeric ratio) mixtures can be quite challenging as enantiomers have the same 
physical properties (melting point, boiling point, polarity etc.) and the same reactivity in 
achiral environments. Therefore, separation or purification through commonly used 
techniques such as column chromatography or distillation that rely solely on physical 
properties cannot be utilized. Single enantiomers are often obtained through specialized 
chromatography, crystallization or asymmetric synthesis.  
1.4.1 Chromatography 
 The separation of enantiomers through chromatography can be possible through 
the design of chiral columns that take advantage of the specific spatial orientation of the 
chiral molecules. These columns are coated with a chiral stationary phase (CSP) that 
provides a chiral environment for the molecules that go through them. Examples of such 
coatings include oligosaccharides such as cyclodextrin,[9] polysaccharides, proteins, or 
macrocyclic antibiotics.[3] Even though most of these techniques are very efficient in 
separating enantiomers and providing a quantitative analysis of mixtures, large scale 
separations of drugs that will be released in the market are often done by much more 
sophisticated techniques. Two of the most effective ones are supercritical fluid 
chromatography (SFC) and simulated moving bed (SMB) chromatography.[6] While SFC 
utilizes carbon dioxide as a mobile phase, and SMB relies on the use of highly 
engineered systems of columns, they are both very expensive methods because of the 
cost of the chiral columns used on a preparative scale. 
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1.4.2 Crystallization 
 One other method of enantiomeric resolution is crystallization, and this technique 
has been explored since pioneered by Pasteur in 1848 via his observations of sodium 
ammonium tartrate.[10],[6] Enantiomers can be separated through fractional crystallization 
that follows the formation of diastereomeric salts or through preferential 
crystallization/enrichment where the preferred enantiomer is crystallized directly.[10] The 
development of efficient methods, however, can be quite challenging as phenomena 
related to nucleation and growth are still not well understood.[11] The formation and 
separation of diastereomeric salts depends on the chiral compound that introduces the 
new chiral center, the resolving agents, as well as the solvent system used to separate 
the pair.[12] On the other hand, the direct enrichment technique requires the 
determination of an ideal temperature and solvent system established through the 
analysis of binary and tertiary phase diagrams while taking into consideration key 
solubility data.[6]  
1.4.3 Asymmetric synthesis  
 Alternatively, asymmetric synthesis or enantioselective synthesis enables 
chemists to design reactions that favor the formation of one of the enantiomers. From 
mimicking enzyme specificity to the synthesis of chiral auxiliaries, the introduction of 
biocatalysts[13] or enantioselective catalysis, asymmetric synthesis is a field that 
continues to grow.[14] The efficiency of these reactions depends on how enantiopure or 
enantioenriched the final products are as well as how tolerant the reactions are to 
different functional groups. The enantiopurity is assessed through enantiomeric excess 
(ee) which is calculated by subtracting the percentage of the minor enantiomer from the 
major enantiomer (ee= %major- %minor).  
7 
 One form of asymmetric synthesis directly “borrows” from nature by using readily 
available biocatalysts to perform enantioselective reactions. Biocatalysts have been 
widely used in the biocatalytic asymmetric reductions of cyclic substrates.[13] One 
example is the use of baker’s yeast to selectively reduce 2,2- dimethylcyclohexane- 1,3- 
dione 8 to (S)- hydroxyketone 9 (Figure 5).[15] This was the first large scale synthesis of 
9, and it allowed for the use of this compound as a chiral building block. Since then 
hydroxyketone 9 has been used in the synthesis of many naturally occurring biologically 
active compounds such as fregenedadiol 10, a natural bicyclic diterpene.[16] 
 
OO
baker's
yeast
(S)
OHO
52% yield
99% ee HO
OH
fregenedadiol
8
9
10  
Figure 5. Biocatalytic Asymmetric Reduction with Baker’s Yeast 
 
 
 When not borrowing from nature, synthetic chemists often draw inspiration from 
mechanistic patterns observed in enzymes. The proline-catalyzed asymmetric aldol 
reaction is one example of such cases. Class I aldolases catalyze reactions of carbonyl 
compounds to synthesize β-hydroxyl carbonyl compounds via an enamine pathway.[17] 
List et al. then mimicked these aldolases to synthesize aldol products 14  in very good 
enantioselectivity by using L-proline 12.[18] This is a very important breakthrough as it is 
the first example of a nonmetallic small-molecule catalyst for direct intermolecular 
asymmetric aldol reactions (Figure 6). 
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Figure 6. The First Example of Direct Intermolecular Asymmetric Aldol Reactions 
In enantioselective catalysis chiral ligands and catalysts may or may not have a 
direct correlation to patterns observed in nature but provide a chiral environment for 
asymmetric synthesis to take place. For example, bis(oxazoline) ligands 17, inspired by 
the ligand framework of vitamin B12, are found to catalyze Diels-Alder, Mukaiyama aldol, 
conjugate addition, cyclopropanation, and aziridation reactions. In contrast, BINOL 2, 
and BINAP 3 catalysts, completely synthetic molecules, have also been found to 
catalyze a variety of reactions. Salen complexes 15, TADDOL 16, and Cinchona alkaloid 
derivatives 18, are further examples of chiral ligands and catalysts that are used to 
catalyze enantioselective reactions (Figure7).[19] 
Figure 7. Chiral Ligands and Catalysts 
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1.5 Desymmetrization  
 One of the types of reactions that can be catalyzed by chiral catalysts is 
desymmetrization. This methodology has been very successful from the 1990s until now 
in synthesizing chiral molecules starting from meso anhydrides, meso ketones, divinyl 
carbinols, meso dienes, achiral epoxides, and even developing alcohol protection 
strategies.[20] The essence of this methodology lies in the plane of symmetry that exists 
in the prochiral intermediate (Figure 8). When this plane of symmetry is broken, a 
stereocenter is introduced. Ideally, when this process is catalyzed by chiral catalysts, the 
final product will be enantioenriched or enantiopure.  
 
R R'plane of
symmetry R R'
X
Xchiral
reagent
prochiral
molecule enantioenriched
product
Mirror plane
chiral catalysts
or enzymes
Chiral Product
Theoretically
up to 100% yield
Y
X
 
 
Figure 8. Desymmetrization 
 
 
1.6 Conclusions 
 Chiral compounds are commonly found in nature and their purification as well as 
their synthesis can be very challenging. To overcome different obstacles chemists have 
tried to create chiral environments that would either differentiate between the 
enantiomers and aid in their separation, or help the reaction proceed in a certain 
direction to obtain enantiopure or enantioenriched compounds. The more tolerant to a 
wide substrate scope these reactions are and the better the enantioselectivity, the more 
successful the asymmetric synthesis. Therefore, it is very important that chemists 
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continue to develop methodologies and strive to synthesize complex and novel scaffolds 
through highly enantioselective reactions, and to test their applicability in a variety of 
substrates. The following chapter discusses the asymmetric synthesis of such scaffolds 
through a phosphoric acid catalyzed desymmetrization. This asymmetric internal 
cyclization methodology has been previously developed in the Petersen group, and this 
project aims to test its applicability in synthesizing enantioenriched spirocycles. 
11 
CHAPTER II 
 
ASYMMETRIC SYNTHESIS OF SPIROCYCLES 
 
 
2.1 Introduction 
 This project explores the asymmetric synthesis of spirocycles, cyclic compounds 
that are linked together by a common atom (Figure 9). The spirocyclic motif itself is very 
important as it can be found in many pharmaceuticals and natural products. Depending 
on the atoms attached to the central atom, these compounds can be classified into 
spirocycles with a non-quaternary carbon spiro center, or spirocycles with a quaternary 
carbon spiro center 20. Compounds such as 19 have heteroatoms attached to the 
spirocenter, while compounds like 20 have only carbon atoms attached to the central 
attom. 
 
 
Figure 9. Types of Spirocycles 
 
 
 The project’s main focus is the synthesis of spirocycles with quaternary C spiro 
centers, and even more specifically of spirolactones 21 or spirolactams 22. Important 
examples of spirolactams in nature include horsfiline 23 which is used as an analgesic[21] 
and azaspirene 24 which is used as an angiogenesis inhibitor (Figure 10).[22] Examples 
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of spirolactones with a tertiary C spiro centers include drospirenone 25 which is a 
synthetic compound used as an oral contraceptive[23] or abyssomycin C 26 which is used 
as an antimicrobial.[24] On the other hand, spirosesquiterpenes 27 and 28 are two of the 
very few examples of naturally occurring spirolactones with a quaternary C spiro 
center.[25] The scarcity of this motif in nature has been of great interest to the Petersen 
group. The 5 new spirocycles that this project introduces are scaffolds that have been 
underexplored and may have use for development in drug discovery projects. Therefore, 
this work not only presents an application of the previously developed enantioselective 
cyclization method by the Petersen group but introduces novel spirocyclic scaffolds that 
contain important motifs.  
 
 
Figure 10. Biologically Active Spirocycles 
 
 
2.2 Previous Results 
 As previously mentioned, the methodology used to synthesize the proposed 
spirolactone scaffolds has been previously developed in the Petersen lab and enables 
the enantioselective cyclization of prochiral intermediates via a chiral Brønsted acid 
catalyzed desymmetrization (Figure 11).[26] Prochiral diesters 29 are synthesized from 
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readily available starting materials and undergo a Brønsted acid catalyzed cyclization (5 
mol% TRIP) that destroys the symmetry in the molecules to obtain chiral lactones 31a-g 
in very good yield and enantiomeric excess. The catalyst used in this process is a 
BINOL phosphoric acid catalyst known as TRIP 30 which exhibits axial chirality and 
introduces a chiral environment in which the reaction can take place. 
Figure 11. Previous Results 
Density Functional Theory (DFT) calculations of an analogous kinetic resolution 
support a mechanism in which the reaction proceeds via a dual activation of the carbonyl 
and the hydroxyl group.[27] The acidic proton of the Brønsted acid activates the carbonyl 
while the Lewis basic oxygen hydrogen bonds to the hydroxyl group to lock the 
intermediate in a certain conformation and enable the cyclization (Figure 12). The bulky 
groups on both sides of the catalyst make it possible for the cyclization to be favored in 
one direction 32 as the other possible conformer 33 is disfavored because of steric 
clashes.  
14 
Figure 12. Proposed Activation 
2.3 Application of the Methodology in Current Work 
The Petersen group’s interest in the asymmetric synthesis of novel small 
molecules led to the application of the above described desymmetrization in the 
preparation of enantioenriched spirocycles. Unlike the previous prochiral diesters 29, the 
new diesters 34 have two nucleophilic chains that would allow for consecutive 
cyclizations at the two electrophilic carbonyls (Figure 13). A desymmetrization is used to 
form the first ring which is depicted below in blue and set the stereocenter. The second 
cyclization (depicted in red) can then be performed via achiral acid catalysis or a 
coupling reaction. While the first cyclization is enantioselective, the second does not 
require the use of the chiral Brønsted acid as the absolute stereochemistry has already 
been set. 
32 33
15 
 
Figure 13. Applied Strategy 
 
 
 This strategy was used to synthesize seven different substrates (Figure 14). With 
the exception of compound 21, all the rest of the substrates had not been previously 
described in literature. Both compound 21 and 37 were first introduced in the group by 
Dr. Jennifer Wilent, a former PhD student. The combined efforts of her and Kyla Stingley 
(former M.S. student) on the synthesis of compound 38 provided data on the 
characterization of this compound. However, they both faced challenges in determining 
the enantiomeric excess of 38. Amber Kelley, a current PhD student, introduced 
compound 39 and 42 to the substrate scope, and was able to grow crystals of 42 that 
helped determine its absolute configuration. This work highlights the effort towards the 
determination of the enantiomeric excess of compound 38 and its precursor, as well as 
its enantioenrichment by recrystallization, and the synthesis of compounds 40 and 41. 
Attempts towards understanding the decrease in enantiomeric excess during the second 
cyclization will also be discussed.   
16 
 
Figure 14. Substrate Scope 
 
 
2.4 Results and Discussions 
2.4.1 Synthesis and recrystallization of compound 38 
 Compound 38 was of great interest to the group as it was the second spirolactam 
scaffold introduced in the substrate scope. As previously mentioned, several members of 
the group have worked on obtaining the necessary data required for publishing this 
substrate.  
 Spirocycle 38 had been previously synthesized as a crystalline white solid by 
members of the Petersen group the readily available di-tert-butyl malonate 43 served as 
a starting material for all the substrates and underwent alkylation with sodium hydride 
(NaH), 44 and anhydrous tetrahydrofuran (THF) to obtain compound 45 in 68% yield 
(Figure 15). Intermediate 45 then underwent another alkylation with NaH, N-tosyl 
aziridine 46 and anhydrous THF to obtain compound 47 in 48% yield. The protected 
alcohol in this intermediate was then deprotected following a hydrogenolysis reaction 
with Pd(OH)2/C in ethyl acetate which yielded compound 48 in 96% yield. The prochiral 
diester 48 was used directly to perform the chiral cyclization with 10 mol% of (S)-TRIP 
17 
30a in dichloroethane for 9 days to yield compound 49 with 92% yield. While they were 
able to synthesize spirocycle 38 through cyclization with trifluoroacetic acid, the group 
was not able to obtain consisted results while determining the enantiomeric excess of 
lactone 49 or spirocycle 38. The first goal of this project was to address these issues by 
working on developing HPLC methods that would help determine the ee values.  
 
 
Figure 15. Steps Towards the Synthesis of Compound 38 
 
 
 After multiple attempts of resolving the issues faced before in separating the 
enantiomers of 49 an enantiomeric excess of 84% was obtained in a normal phase chiral 
HPLC, but with no complete baseline separation. Using the previously synthesized 
compound 49, the last cyclization was then performed in dichloromethane to obtain 
spirocycle 38 in 80% yield and 60% ee. A reverse phase chiral HPLC was used to 
separate these enantiomers and establish the ee values.  
18 
 
Figure 16. Recrystallization of Compound 38 
 
 
 The Petersen group was also interested in observing the effects of 
recrystallization in the enantiomeric excess since this compound was one of the few 
crystalline scaffolds that was synthesized. Several solvent systems were attempted and 
recrystallization with ethyl acetate and hexanes resulted in an enantiomeric excess of 
85% after filtration with 87% recovery (Figure 16). This increase by 25% in ee values is a 
great example of how recrystallization can be used to for enantioenrichment of 
crystalline compounds with modest enantiomeric excess.  
2.4.2 Attempts towards the synthesis of compound 41 
 Another interesting addition to the substrate scope would be the synthesis of 
spirocycle 41 which contains a seven membered lactone. Unlike the rest of the 
substrates, the synthesis of this compound was more challenging. Similar to the 
previous synthesis, di-tert-butyl malonate was used as a starting material to obtain the 
prochiral diester 51 which contains two protected nucleophilic chains (Figure 17). The 
first two alkylating steps were performed in dimethylformamide (DMF) while using NaH 
as a base. The first alkylation utilized 44 as an alkylating agent while the second one 
utilized 50. The different protecting groups on the two alcohols allows for the selective 
deprotection of only one of them by a hydrogenolysis reaction with Pd(OH)2 on carbon. 
The accessible free alcohol was then utilized in the chiral cyclization with 10 mol% of 
19 
(S)-TRIP in dichloroethane to obtain 53 in 63% yield and 40% ee. The second alcohol 
was then deprotected with K2CO3 in methanol in 94% yield. Unlike the previous 
synthesis, reaction with trifluoroacetic acid in dichloromethane does not enable the 
second cyclization but removes the tert-butyl group and generates carboxylic acid 55 
which is isolated in 99% yield.  
 
 
Figure 17. Steps Towards the Synthesis of Compound 41 
 
 
 An intramolecular transesterification of compound 54 is more challenging than 
the rest of the substrates as the formation of 7-membered ring is difficult.  Common 
approaches towards the synthesis of macrocycles involve methods that allow the 
cyclization to proceed through intermediates where the carboxylate is decorated with an 
exceptionally good leaving group.[28] Such reactions are known as coupling reactions 
and can be used to form a macrocyclic ester from an alcohol and a carboxylic acid. The 
two different coupling reactions attempted in this synthesis were Steglich Esterification 
(DCC/DMAP) and the carbonyldiimidazole coupling (Figure 18).  Even though traces of 
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what was believed to be the product were observed via NMR, compound 41 was not 
isolated using N, N'-dicyclohexylcarbodiimide 56 and 4-dimethylaminopyridine (DMAP). 
Dicyclohexylurea (DCU) 59, a biproduct of the reaction is a very soluble compound that 
has the tendency to travel with the solvent in column chromatography, making it difficult 
to obtain pure product, especially on small reaction scales. Even after attempts of 
precipitating DCU out of solution in cold acetonitrile, compound 41 was not isolated. 
Alternatively, coupling with CDI was the second approach used where what is believed 
to be spirocycle 41 was obtained in 18% yield.  However, the enantiomeric excess of the 
final compound was only 25% and this coupled with the modest yield led to the exclusion 
of this substrate from the publication. 
 
 
Figure 18. Coupling Reactions 
 
 
2.4.3 Synthesis of compound 40 
 The first step towards the synthesis of compound 40 involved the alkylation of di-
tert-butyl malonate with alkylating agent 65. Compound 65 was synthesized from o-
cresol 63 which underwent a protecting step with tert-butyldimethylsilyl chloride (TBSCl) 
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and was brominated with azobisisobutyronitrile (AIBN) and N-bromosuccinimide (NBS) 
in benzene as previously published (Figure 19).[29]  
 
OH
TBSCl
Imidazole
DMF
OTBS
AIBN
NBS
Benzene
75% 91%
OTBS
Br
63 64 65  
Figure 19. Synthesis of Alkylating Agent 65 
 
 
 The prochiral diester 68 that was synthesized after the second alkylation and the 
removal of the acetyl protecting group, underwent a cyclization with (R)- TRIP 30b that 
yielded the TBS protected enantioenriched lactone 69 in 81% yield (Figure 20). The 
enantiomeric excess of the first cyclization was determined after the removal of the TBS 
group and was determined to be 76%. Upon cyclization with p-toluenesulfonic acid (p-
TSA) in dichloroethane for 48 hours, the enantiomeric excess decreased to 72% with a 
low yield of 34%. Alternatively, when the reaction was heated to reflux, and a second 
equivalence of p-TSA was added to the mixture, the reaction went to completion but the 
spirocycle 40 resulted racemic (0% ee). Therefore, to avoid a decrease in enantiomeric 
excess, the yield of the reaction was sacrificed.  
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Figure 20. Steps Towards the Synthesis of Spirocycle 40 
 
 
2.4.4 Attempts in understanding stereochemical retention  
 The decrease in enantiomeric excess that was observed in all the substrates 
upon the 2nd cyclization to form the spirocycles, led to the investigation of the 
mechanism of reaction via the cyclization of compound 71 (Figure 21). One possible 
explanation to this phenomenon lies in the fact that there are 2 possible electrophilic 
sites in 71 for cyclization. If the acid used in this step activates the ester carbonyl (red 
pathway) the synthesized spirocycle 37 will retain its stereochemistry and the 
enantiomeric excess will not decrease. However, if the acid activates the lactone 
carbonyl (blue pathway) the previously synthesized lactone will open to generate lactone 
72 which will then yield spirocycle 37 with inverted stereochemistry.  
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Figure 21. Pathway for Inversion of Stereochemistry 
 
 
 The question that arises after considering this pathway is whether the 
stereochemistry set during the first cyclization is retained and simply decreased because 
of this phenomenon or it is completely inverted to the opposite configuration. Two 
different approaches were strategized to give more insight into this matter (Figure 22). 
Approach A required the synthesis of compound 72. Assuming that a time dependent 
NMR study of the cyclization of compound 71 to 37 would show traces of compound 72 
forming along the way if the blue “inversion” pathway was followed, the synthesis of 
compound 72 would be helpful in the accurate assignment of the collected NMR spectra. 
Approach B required the synthesis of compound 37 through a coupling reaction. Since 
the second ring of spirocycle 37 has been previously synthesized through acid catalysis, 
a coupling reaction would be able to bypass the issues that come with catalysis and 
yield a compound that retains the stereochemistry. Spirocycle 37 has been found to 
rotate plane-polarized light to the left (negative sign). Therefore, evidence in support of 
stereochemical retention could be provided if the newly synthesized spirocycle also 
rotates plane-polarized light to the left.  
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Figure 22. Approaches Towards Understanding Stereochemical Retention 
 
 
 However, even though intermediate 76 was successfully synthesized, lactone 72 
was not isolable as it was immediately converted to lactone 71 (Figure 23). This 
indicates that the formation of the γ-lactone is more thermodynamically favorable. The 
reaction is also not reversible and the formed γ-lactone appears to be more stable. This 
can be due to the length of chain containing the alcohol as well as its spatial orientation 
that does not favor the addition to the lactone carbonyl without the presence of catalytic 
amounts of acid.  
 
 
Figure 23. Attempts Towards the Synthesis of Compound 72 
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 Approach B was also not fruitful as the deprotection of compound 80 resulted in 
the synthesis of spirocycle 37 (Figure 24). This undesired cyclization did not allow for a 
coupling reaction, and therefore the optical rotation of the final compound could not be 
compared to the previously synthesized spirocycle.  
 
 
Figure 24. Attempts and Challenges Towards the Synthesis of Compound 37 
 
 
2.4.5 Published results  
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Figure 25. NMR Study 
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Even though the approaches mentioned above provided inconclusive results, 
previous work from Tyler Wilson, a former M.S. student, provided evidence in support of 
the retention of stereochemistry through NMR studies of the conversion of compound 71 
to 37 (Figure 25).[30] In this study the rate of disappearance of protons Ha matches the 
rate of appearance of protons Hb, and no traces of the δ- hydroxy lactone were 
observed. The absence of substantial amounts of compound x, suggests that the major 
pathway is the red one (Figure 21), and the stereochemistry set during the first 
cyclization is preserved. 
Additionally, four more substrates were introduced to the scope of this reaction 
by the rest of the Petersen group and X-ray crystallography of compound 42 was able to 
establish its absolute configuration (Figure 26). The rest of the stereochemistry was 
assigned to the molecules by analogy. Good to moderate ee values were also reported 
for all six of the published molecules. 
 
 
Figure 26. Published Results 
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2.5 Conclusions  
 This work focuses on the applications of a previously developed methodology on 
the synthesis of enantioenriched spirocycles, motifs that are present in many 
pharmaceuticals and natural products. The methodology is known as desymmetrization 
and enables the formation of enantioenriched molecules through a chiral Brønsted acid 
catalyzed internal cyclization. Six substrates were synthesized by the combined effort of 
several members of the group, and this work discussed the synthesis of some of them 
as well as challenges that were faces while trying to introduce a seventh substrate. 
Unfortunately, both approaches that would provide evidence towards the stereochemical 
retention of the substrates were not successful. Overall, this project introduces the 
synthesis of six novel and enantioenriched spirocyclic scaffolds, five of which had a 
quaternary carbon center.
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CHAPTER III 
EXPERIMENTAL 
 
 
3.1 General Information 
Unless noted, all solvents and reagents were obtained from commercial sources 
and used without further purification; anhydrous solvents were dried following standard 
procedures. The 1H and 13C nuclear magnetic resonance (NMR) spectra were plotted on 
400 and 500 MHz spectrometer using CDCl3 as a solvent at room temperature. The 
NMR chemical shifts (δ) are reported in ppm. Abbreviations for 1H NMR: s = singlet, d = 
doublet, m = multiplet, b = broad, t = triplet, q = quartet, quint = quintet. The reactions 
were monitored by TLC using silica G F254 precoated plates. Flash chromatography 
was performed using flash grade silica gel (particle size: 40-63 μm, 230 × 400 mesh). 
Enantiomeric excess was determined by GC analysis and HPLC analysis. IR data was 
obtained with a FTIR spectrometer one with frequencies reported in cm-1. High 
Resolution Mass Spectra were acquired on an Orbitrap XL MS system. The specific 
rotations were acquired on an analytical polarimeter.
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3.2 Synthesis of Compound 38 
 
 
 
Figure 27. Compound 38 
 
 
 To a solution of lactone intermediate 49 (42.0 mg, 0.110 mmol) in CH2Cl2 (2 mL) 
was added excess trifluoroacetic acid (2 mL) and the solution was stirred until reaction 
completion was determined by TLC analysis. The reaction was extracted with ethyl 
acetate (2 x 10 mL) and H2O (1 x 10 mL). The organic phase was dried over MgSO4 and 
concentrated to afford compound 38 as white solid (29 mg, 85% yield, 60% ee). The 
compound was then dissolved in ethyl acetate and hot hexanes and let to cool down to 
room temperature. The recrystallized material was filtered and rinsed with cold hexanes 
to result in 85% ee and 87% recovery. 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8 Hz, 
2H), 7.34 (d, J = 8 Hz , 2H), 4.48 (m, 1H), 4.32 (m, 1H), 4.07 (m, 2H), 2.73 (m, 1H), 2.52 
(m, 1H), 2.43 (s, 3H), 2.16 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 174.3, 170.1, 145.9, 
134.2, 130.0, 128.2, 66.9, 53.1, 45.1, 32.1, 28.9, 21.9; IR (neat) cm-1 2923, 1765, 1716, 
1358, 1348, 1167, 1105, 1024, 668, 585; HRMS (C14H15NO5S, ESI): calculated 
310.0744 [M+Na]+1, found 310.0745, 𝛼  = –35.2° (c = 0.25, CHCl3); mp = 134.2 - 
136.6°C. 
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3.3 Synthesis of Compound 41 
 3.3.1 Synthesis of intermediate 45  
 
 
Figure 28. Intermediate 45 
 
 
 Di-tert-butyl malonate (500 mg, 2.3 mmol) was added dropwise to a solution of 
sodium hydride (60% in mineral oil, 138mg, 3.5 mmol) in DMF (23 mL), and the solution 
was stirred until gas evolution was complete. Benzyl 2-bromoethyl ether 44 (497 mg, 2.3 
mmol), was added to the reaction mixture and the solution was stirred until reaction 
completion was determined by TLC analysis (24 hours). The reaction was quenched 
with saturated NH4Cl (10 mL) at 0°C, phases were separated, and aqueous phase was 
extracted with ethyl acetate (2 x 10 mL). The organic phase was dried over anhydrous 
MgSO4 and concentrated. The residue was purified by flash chromatography on silica 
gel (5→20 % ethyl acetate /hexanes) to obtain monoalkylated malonate as a colorless 
oil (648 mg, 80% yield). 1H NMR (500 MHz, CDCl3) δ 7.33 (m, 5H), 4.48 (s, 2H), 3.50 (t, 
J = 6.2 Hz, 2H), 3.39 (t, J = 7.4 Hz, 1H), 2.12 (dt, J = 7.4, 6.2 Hz, 2H), 1.44 (s, 18H).13C 
NMR (126 MHz, CDCl3) δ 168.9, 138.4, 128.5, 127.8, 127.7, 81.5, 73.1, 67.6, 51.0, 28.9, 
28.0 
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3.3.2 Synthesis of intermediate 51 
 
 
Figure 29. Intermediate 51 
 
 
 The monoalkylated malonate 45 (250 mg, 0.71 mmol) was added to a solution of 
sodium hydride (60% mineral oil, 43 mg, 1.1 mmol) in DMF (7 mL). The solution was 
stirred until gas evolution was complete. To the reaction mixture was added 4-
bromobutyl acetate 50 (209 mg, 1.1 mmol) at 0°C, and the solution was stirred until 
reaction completion was determined by TLC analysis (24 hours). The reaction was 
quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, and aqueous 
phase was extracted with ethyl acetate (2 x 10 mL). The organic phase was dried over 
anhydrous MgSO4 and concentrated. The residue was purified by flash chromatography 
on silica gel (5→ 20% ethyl acetate/hexanes) to obtain the dialkylated malonate 51 as a 
colorless liquid (281 mg, 85% yield). 1H NMR (500 MHz, CDCl3) δ 7.10 (m, 5H), 4.46 (s, 
2H), 4.01 (t, J = 6.6 Hz, 2H), 3.42 (t, J = 7.0 Hz, 2H), 2.16 (t, J = 7.0 Hz, 2H), 2.01 (s, 
3H), 1.82 (m, 2H), 1.59 (m, 2H), 1.41 (s, 18H), 1.23 (m, 2H); 13C NMR (126 MHz, CDCl3) 
δ 171.2, 170.7, 138.3, 128.4, 127.8, 127.7, 81.2, 73.0, 66.2, 64.2, 57.0, 31.6, 29.0, 27.9, 
21.1, 20.6; IR (neat) cm-1 2975, 1722, 1366, 1239, 1147, 1111; HRMS (C26H40O7, ESI): 
calculated 487.2666 [M+Na]+1, found 487.2656. 
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3.3.3 Synthesis of intermediate 52 
 
 
Figure 30. Intermediate 52 
 
 
 To a solution of the dialkylated intermediate 51 (250 mg, 0.54 mmol) in ethyl 
acetate (11 mL) was added Pd(OH)2 (20% on carbon, 38 mg, 0.27 mmol) and the 
solution was stirred under hydrogen pressure using a balloon filled with hydrogen gas at 
room temperature until reaction completion was determined by TLC analysis. The 
reaction mixture was filtered through a plug of Celite® and the filtrate was concentrated 
under vacuum, to afford compound 52 as colorless oil (198 mg, 99% yield). 1H NMR 
(500 MHz, CDCl3) δ 4.04 (t, J = 6.5 Hz, 2H), 3.65 (t, J = 6.6 Hz, 2H), 2.07 (t, J = 6.6 Hz, 
2H), 2.01 (s, 3H), 1.84 (m, 2H), 1.62 (m, J = 6.6 Hz, 2H), 1.44 (s, 18H), 1.26 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 171.2, 81.7, 64.2, 59.1, 57.3, 35.2, 32.9, 29.0, 27.9, 21.1, 
20.7;  IR (neat) cm-1 3451, 2974, 1720, 1366, 1238, 1034, 846; HRMS (C19H34O7, ESI): 
calculated 375.2383 [M+Na]+1, found 375.2368. 
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3.3.4 Synthesis of intermediate 53 
 
 
Figure 31. Intermediate 53 
 
 
 To a solution of acid 52 (190 mg, 0.50 mmol) in dichloroethane (5 mL) was 
added compound (S)- TRIP 30a (38 mg, 0.050 mmol) and the solution was stirred for 10 
days at room temperature. The reaction was extracted with ethyl acetate (2 x 10 mL) 
and H2O (1 x 10 mL). The organic phase was dried over MgSO4 and concentrated to 
afford lactone intermediate 53 as a colorless liquid (95.8 mg, 63% yield).1H NMR (500 
MHz, CDCl3) δ 4.31 (m, 2H), 4.06 (t, J = 6.5 Hz, 2H), 2.66 (m, 1H), 2.19 (m, 1H), 2.05 
(m, 1H) 2.03 (s, 3H), 1.75 (m, 1H), 1.66 (m, 2H), 1.48 (m, 1H), 1.47 (s, 9H), 1.33 (m, 
1H); 13C NMR (126 MHz, CDCl3) δ 175.2, 171.2, 168.6, 83.1, 66.2, 64.1, 54.8, 33.7, 
32.0, 28.8, 27.90, 27.89, 27.88, 21.4, 21.1; IR (neat) cm-1 2976, 1772, 1728, 1242, 1028; 
HRMS (C15H24O6, ESI): calculated 323.1465 [M+Na]+1, found 323.1451. 
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3.3.5 Synthesis of intermediate 54 
 
 
Figure 32. Compound 54 
 
 
 To a solution of intermediate 53 (100 mg, 0.41 mmol) in methanol (8 mL) was 
added K2CO3 (226 mg, 1.6 mmol), and the solution was stirred at room temperature until 
reaction completion was determined by TLC analysis. The reaction mixture was diluted 
with CH2Cl2 and was extracted with CH2Cl2 (2 x 15 mL) and H2O (1 x 10 mL). The 
organic layer was dried over MgSO4 and concentrated to afford compound 54 as a 
colorless oil (78 mg, 94% yield, 40% ee). 1H NMR (500 MHz, CDCl3) δ 4.3 (m, 2H), 3.66 
(t, J = 5 Hz, 2H), 2.65 (m, 1H), 2.22 (m, 1H), 2.05 (td, J = 10, 5 Hz, 1H), 1.75 (td, J = 15, 
10 Hz 1H), 1.59 (m, 4H), 1.47 (s, 9H), 1.33 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 175.4, 
168.7, 83.1, 66.3, 62.3, 54.9, 33.5, 32.6, 31.9, 27.9, 21.0; HRMS (C13H22O5, ESI): 
calculated 259.154 [M+H]+1, found 259.1539. 
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3.3.6 Synthesis of compound 41 
 
 
 
Figure 33. Compound 41 
 
 
 To a solution of alcohol 54 (125 mg, 0.42 mmol) in CH2Cl2 (1 mL) was added 0.2 
mL of trifluoroacetic acid (excess). The reaction mixture was stirred at room temperature 
until reaction completion was determined by TLC analysis. The reaction was diluted with 
CH2Cl2 and was extracted with CH2Cl2 (2 x 15 mL) and acidic aqueous layer (1 x 10 mL). 
The organic layer was dried over MgSO4 and concentrated to afford a carboxylic acid 
intermediate 55 as a colorless oil (100 mg, 99% yield). 1H NMR (400 MHz, CDCl3) 
δ 8.38 (bs, 1H), 4.38 (m, 4H), 2.78 (m, 1H), 2.27 (m, 1H), 212 (m, 1H), 2.81 (m, 1H), 
1.55 (m, 1H), 1.40 (m, 1H). 
 The carboxylic acid (43 mg, 0.22 mmol) was concentrated in a scintillation vial 
which was later purged with argon. Acetonitrile (4.3 mL, 0.05M) and carbonyldiimidazole 
(38 mg, 0.24 mmol) were then added to the vial, and the reaction was stirred overnight. 
The mixture was concentrated and purified via column chromatography (60% ethyl 
acetate/hexanes) to obtain the product 41 as a white solid (7 mg, 18%). 1H NMR (500 
MHz, CDCl3) δ 4.83 (m, 1H), 4.36 (m, 2H), 4.24 (m, 1H), 2.96 (m, 1H), 2.24 (m, 2H),  
2.07 (m, 1H), 1.93 (m, 2H), 1.80 (m, 1H), 1.73 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 
174.5, 170.7, 69.8, 65.7, 56.0, 34.7, 32.0, 28.8, 24.1. 
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3.4 Synthesis of Compound 40 
 3.4.1 Synthesis of intermediate 65 
 
 
Figure 34. Intermediate 65 
 
 
 Dry DMF (10 mL, 0.1 M) was added to a 50 mL flask followed by o-cresol 63 (1.0 
mL, 10 mmol). Imidazole (1.50 g, 22 mmol) was added next followed by tert-
butyldimethylsilyl chloride (1.66 g, 11 mmol). The reaction was left stirring overnight and 
quenched with water after 21 hours. The mixture was extracted with ethyl acetate, dried 
over MgSO4 and concentrated in vacuo. The mixture was purified via column 
chromatography (10% ethyl acetate /hexanes) to obtain 64 as a colorless oil (1.65 g, 
75% yield). 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J= 10 Hz, 1H), 7.05 (t, J = 10 Hz, 1H), 
6.85 (t, J = 10 Hz, 1H), 6.77 (d, J= 5 Hz, 1H), 2.21 (s, 3H), 1.02 (s, 9H), 0.22 (s, 6H); 13C 
NMR (126 MHz, CDCl3) δ 154.0, 131.0, 129.0, 126.7, 121.1, 118.6, 25.9, 18.4, 17.0, -
4.1. 
 To a 100 mL round bottom flask was added benzene (20 mL) followed by 
compound 64 (1.65 g, 7.4 mmol). azobisisobutyronitrile (183 mg, 1.1 mmol) and N-
bromosuccinimide (1.45 g, 8.2 mmol) were added next, and the reaction was left stirring 
for 4 hours under reflux (90oC). After 4 hours the reaction mixture was cooled to room 
temperature and filtered through a fritted funnel with 1 inch of silica while being rinsed 
with hexanes. Compound 65 was obtained as a colorless oil without the need of 
purification (1.99 g, 91% yield). 1H NMR (500 MHz, CDCl3) δ 7.32 (d, J = 10 Hz, 1H), 
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7.17 (t, J = 10 Hz, 1H), 6.91 (t, J = 15 Hz, 1H), 6.80 (d, J = 15 Hz, 1H), 4.52 (s, 2H), 1.04 
(s, 9H), 0.28 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 154.0, 131.0, 130.0, 128.5, 121.4, 
118.7, 29.5, 25.9, 18.4, -4.0. 
3.4.2 Synthesis of intermediate 81 
 
 
Figure 35. Intermediate 81 
 
 
 To a 50 mL round bottom flask containing NaH (60% dispersion, 94 mg, 2.3 
mmol), was added di-tert-butyl malonate (0.35 mL, 1.6 mmol), THF (16 mL), and 65 (570 
mg, 1.9 mmol). The mixture was stirred overnight at room temperature, then quenched 
with H2O (10 mL) and diluted with ethyl acetate (30 mL). The layers were separated, and 
the organic layer was washed with water (10 mL), dried over MgSO4, and concentrated 
in vacuo. The resulting crude material was purified using silica gel column 
chromatography (10% ethyl acetate/hexanes) to afford the mono alkylated intermediate 
81 as a white solid (580 mg, 85% yield) which was taken directly on to the next step. 1H 
NMR (500 MHz, CDCl3) δ 7.11 (m, 1H), 7.08 (m, 1H), 6.82 (m, 1H), 6.76 (m, 1H), 3.60 (t, 
J = 7.9 Hz, 1H), 3.07 (d, J = 7.9 Hz, 2H), 1.39 (s, 18H), 1.00 (s, 9H), 0.25 (s, 6H); 13C 
NMR (126 MHz, CDCl3) δ 168.6, 153.9, 131.4, 128.7, 127.8, 120.8, 118.2, 81.3, 53.4, 
30.5, 28.0, 25.9, 18.3, -4.0; HRMS (C24H40O5Si, ESI): calculated 437.2723 [M+H]+1, 
found 437.2718; mp= 67.8- 69.5°C. 
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3.4.3 Synthesis of intermediate 67 
 
 
Figure 36. Intermediate 67 
 
 
 To a 50 mL round bottom flask containing NaH (60% dispersion, 93 mg, 2.3 
mmol), was added 81 (340 mg, 0.78 mmol), THF (8 mL), and 2-bromoethylacetate 66 
(0.26 mL, 2.3 mmol). The mixture was stirred overnight at room temperature, then 
quenched with H2O (10 mL) and diluted with ethyl acetate (30 mL). The layers were 
separated, and the organic layer was washed with water (10 mL), dried over MgSO4, 
and concentrated in vacuo. The resulting crude material was purified using silica gel 
column chromatography (10% ethyl acetate/hexanes) to afford the dialkylated 
intermediate 67 as a colorless oil (254 mg, 62% yield). 1H NMR (400 MHz, CDCl3) δ 7.15 
(m, 1H), 7.06 (m, 1H), 6.82 (m, 1H), 6.77 (m, 1H), 4.11 (t, J = 8.0 Hz, 2H), 3.26 (s, 2H), 
2.04 (t, J= 8.0 Hz, 2H), 1.95 (s, 3H), 1.44 (s, 18H), 1.00 (s, 9H), 0.21 (s, 6H); 13C NMR 
(101 MHz, CDCl3) δ 170.9, 170.4, 154.3, 131.1, 127.6, 127.4, 119.0, 81.8, 61.4, 58.1, 
32.1, 31.8, 27.9, 26.0, 21.1, 18.4, -4.0; HRMS (C28H46O7Si, ESI): calculated 523.3091 
[M+H]+1, found 523.3087. 
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3.4.4 Synthesis of intermediate 68 
 
 
Figure 37. Intermediate 68 
 
 
 To a 50 mL round bottom flask, was added compound 67 (190 mg, 0.36 mmol) in 
methanol (7 mL), followed by K2CO3 (150 mg, 1.1 mmol). The mixture was stirred at 
room temperature for 30 min and then separated with H2O and Ethyl acetate. The 
aqueous layer was extracted with ethyl acetate (3 x 7 mL) and the combined organic 
layers were dried with MgSO4, filtered and concentrated in vacuo. The mixture was 
purified via column chromatography (20% Ethyl acetate/hexanes) to obtain the product 
68 as a colorless oil (117 mg, 67% yield). 1H NMR (400 MHz, CDCl3) δ 7.15 (m, 1H), 
7.06 (m, 1H), 6.82 (m, 1H), 6.77 (m, 1H), 3.66 (t, J = 6.5 Hz, 2H), 3.27 (s, 2H), 1.98 (t, J 
= 6.5 Hz, 2H), 1.45 (s, 18H), 1.00 (s, 9H), 0.21 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 
171.2, 130.9, 127.6, 127.6, 121.1, 119.2, 81.9, 59.4, 59.0, 36.2, 32.4, 28.0, 26.0, 18.5, -
4.0; HRMS (C26H44O6Si, ESI): calculated 503.2805 [M+Na]+1, found 503.2799. 
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3.4.5 Synthesis of intermediate 69 
 
 
Figure 38. Intermediate 69 
 
 
 To a solution of (R)-TRIP 30b (29.8 mg, 0.040 mmol) in CH2Cl2 (4 mL) was 
added compound 68 (190 mg, 0.40 mmol) and the solution was stirred for 11 days at 
room temperature. The reaction was extracted with ethyl acetate (2 x 10 mL) and H2O (1 
x 10 mL). The organic phase was dried over MgSO4 and concentrated to afford after 
purification (20% ethyl acetate/hexanes) the lactone intermediate 69 as a white solid 
(130 mg, 81% yield). 1H NMR (400 MHz, CDCl3) δ 7.21 (m, 1H), 7.11 (m, 1H), 6.87 (m, 
1H), 6.79 (m, 1H), 4.17 (q, J = 8.5 Hz, 1H), 3.83 (td, J = 8.5, 4.0 Hz, 1H), 3.51 (d, J = 
12.0 Hz, 1H), 3.11 (d, J = 12.0 Hz, 1H), 2.46 (m, 1H), 2.24 (m, 1H), 1.48 (s, 9H), 0.99 (s, 
9H), 0.22 (d, J = 19.7 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 175.8, 169.1, 154.3, 131.8, 
128.4, 126.6, 121.8, 118.6, 83.0, 66.4, 56.4, 31.8, 30.1, 27.9, 25.9, 18.3, -3.8, -4.3; 
HRMS (C26H44O6Si, ESI): calculated 407.2253 [M+H]+1, found 407.2248; mp= 91.5°C- 
93.2°C 
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3.4.6 Synthesis of intermediate 70 
 
 
Figure 39. Intermediate 70 
 
 
 To a 10 mL round bottom flask was added compound 69 (115 mg, 0.28 mmol) 
and dry THF (4 mL). Tetra- n- butylammonium fluoride (0.85 mL. 0.85 mmol) was then 
added to the solution and the reaction was left stirring at 0°C for 2 hours. The mixture 
was separated with H2O (1x 10 mL) and ethyl acetate (2x 10 mL) and dried over MgSO4. 
The crude material underwent column chromatography (30% ethyl acetate/hexanes) to 
obtain 70 as a yellow oil (80 mg, 97% yield, 75% ee). 1H NMR (500 MHz, CDCl3) δ 7.16 
(m, 1H), 7.09 (bs, 1H), 7.06 (m, 1H), 6.89 (m, 1H), 6.85 (m, 1H), 4.31 (m, 1H), 4.22 (td, J 
= 8.0, 4.0 Hz, 1H), 3.30 (d, J = 14.7 Hz, 1H), 3.17 (d, J = 14.7 Hz, 1H), 2.58 (m, 1H), 
2.47 (m, 1H), 1.45 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 177.1, 169.5, 155.1, 121.9, 
120.7, 117.8, 84.4, 56.6, 32.6, 31.3, 27.8; HRMS (C16H20O5, ESI): calculated 293.1389 
[M+H]+1, found 293.1380.  
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3.4.7 Synthesis of compound 40 
 
 
Figure 40. Compound 40 
 
 
 To a 10 mL round bottom flask was added compound 70 (70 mg, 0.24 mmol) 
dissolved in dry dichloroethane (2.5 mL) followed by p-toluenesulfonic acid (41 mg, 0.24 
mmol). The reaction was left stirring at room temperature for 36 hours. The mixture was 
separated with H2O (1x 10 mL) and ethyl acetate (2x 10 mL) and dried over MgSO4. The 
crude material underwent column chromatography (30% ethyl acetate/hexanes) to 
obtain 40 as a white solid (18 mg, 35% yield, 72% ee). 1H NMR (500 MHz, CDCl3) δ 
7.32 (m, 1H), 7.23 (m, 1H), 7.16 (m, 1H), 7.10 (m, 1H), 4.45 (m, 2H), 3.62 (d, J = 16.2 
Hz, 1H), 2.93 (d, J = 16.2 Hz, 1H), 2.62 (m, 1H), 2.23 (m, 1H); 13C NMR (126 MHz, 
CDCl3) δ 173.2, 165.7, 151.0, 128.6, 125.3, 119.6, 116.8, 65.7, 49.2, 33.8, 33.0; HRMS 
(C12H10O4, ESI): calculated 219.0657 [M+H]+1, found 219.0651; 𝛼 = – 9.09° (c = 0.22, 
CHCl3); mp= 140.1 - 141.8°C.  
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3.5 Synthesis of Compound 71 
3.5.1 Synthesis of intermediate 82  
 
 
 
Figure 41. Intermediate 82 
 
 
 To a 25 mL round bottom flask containing NaH (60% dispersion, 83 mg, 2.1 
mmol), was added 45 (365 mg, 1.0 mmol), DMF (10 mL), and 3-bromopropylacetate 74 
(282 mg, 1.6 mmol). The mixture was stirred overnight at room temperature, then 
quenched with H2O (10 mL) and diluted with Ethyl acetate (30 mL). The layers were 
separated, and the organic layer was washed with water (10 mL), dried over MgSO4, 
and concentrated in vacuo. The resulting crude material was purified using silica gel 
column chromatography (20% ethyl acetate/hexanes) to afford the dialkylated 
intermediate 82 as a colorless oil (135 mg, 30% yield). 1H NMR (500 MHz, CDCl3) δ 7.31 
(m, 5 H), 4.46 (s, 2H), 4.00 (t, J= 5Hz, 2H), 3.42 (t, J= 5Hz, 2H), 2.16 (t, J= 5Hz, 2H), 
2.01 (s, 3H), 1.87 (m, 2H), 1.41 (s, 18H). 
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3.5.2 Synthesis of intermediate 76 
 
 
Figure 42. Intermediate 76 
 
 
 To a 10 mL round bottom flask, was added compound 82 (135 mg, 0.30 mmol) in 
MeOH (7 mL), followed by K2CO3 (150 mg, 1.1 mmol). The mixture was stirred at room 
temperature for hour and then separated with H2O and ethyl acetate. The aqueous layer 
was extracted with ethyl acetate (3 x 7 mL) and the combined organic layers were dried 
with MgSO4, filtered and concentrated in vacuo. The intermediate alcohol was isolated 
without purification as a colorless oil (122 mg, 99% yield).  
 To a 10 mL round bottom flask was added the alcohol intermediate (122 mg, 
0.30 mmol) dissolved in dry dichloromethane (3 mL) followed by p-toluenesulfonic acid 
(57 mg, 0.33 mmol). The reaction was left stirring at room temperature for 24 hours. The 
mixture was separated with H2O (1x 10 mL) and ethyl acetate (2x 10 mL) and dried over 
MgSO4. The product was obtained as a colorless oil 76 (72 mg, 70% yield) 1H NMR (500 
MHz, CDCl3) δ 7.31 (m, 5H), 4.46 (q, J= 15, 5 Hz, 2H), 4.25 (m, 2H), 3.61 (m, 2H), 2.32 
(m, 2H), 2.17 (m, 1H), 1.94 (m, 2H), 1.84 (m, 1H), 1.44 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 170.6, 170.4, 138.3, 128.5, 127.8, 127.7, 83.0, 73.1, 68.7, 66.6, 53.7, 35.8, 
28.5, 27.9, 20.7. 
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3.5.3 Synthesis of compound 71 
 
 
Figure 43. Compound 71 
 
 
To a solution of compound 76 (77 mg, 0.23 mmol) in ethyl acetate (5 mL) was 
added Pd(OH)2 (20% on carbon, 16 mg, 0.12 mmol) and the solution was stirred under 
hydrogen pressure using a balloon filled with hydrogen gas at room temperature until 
reaction completion was determined by TLC analysis. The reaction mixture was filtered 
through a plug of Celite® and the filtrate was concentrated under vacuum, to afford 
compound 71 as colorless oil (56 mg, 99% yield). 1H NMR (400 MHz, CDCl3) δ 4.30 (m, 
2H), 3.63 (m, 2H), 2.63 (m, 1H), 2.21 (m, 1H), 2.05(m, 1H), 1.88 (bs, 1H), 1.81 (m, 1H), 
1.67 (m, 1H), 1.53 (m, 1H), 1.44 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 175.5, 168.8, 
98.9, 83.3, 66.3, 62.4, 54.6, 32.2, 30.3, 27.9. 
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3.6 Synthesis of Compound 80 
 3.6.1 Synthesis of intermediate 83  
 
 
Figure 44. Intermediate 83 
 
 
 To a 50 mL round bottom flask containing NaH (60% dispersion, 92 mg, 2.3 
mmol), was added di-tert-butyl malonate 43 (0.518 mL, 2.3 mmol), dry DMF (23 mL) and 
2-bromoethyl acetate 66 (0.280 mL, 2.5 mmol). The mixture was stirred overnight at 
room temperature, then quenched with saturated NH4Cl (10 mL) and diluted with ethyl 
acetate (30 mL). The layers were separated, the organic layer was washed with water 
(10 mL), dried over MgSO4, and concentrated in vacuo. The resulting crude material was 
purified using silica gel column chromatography (10% ethyl acetate/hexanes) to afford 
the mono-alkylated intermediate as a colorless oil (487 mg, 70% yield) which was used 
directly in the next step.  
 The mono-alkylated intermediate (500 mg, 1.7 mmol), was added to a 25 mL 
round bottom flask containing NaH (60% dispersion, 132 mg, 3.3 mmol) and DMF (17 
mL). Next, 3- bromopropylbenzylether 77 (0.440 mL, 2.48 mmol) was added to the 
solution. The mixture was stirred overnight at rt then quenched with H2O (10 mL) and 
diluted with ethyl acetate (30 mL). The layers were separated, the organic layer was 
washed with water (10 mL), dried over MgSO4, and concentrated in vacuo. The resulting 
crude material was purified using silica gel column chromatography (10% ethyl 
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acetate/hexanes) to afford 83 as a colorless oil (600 mg, 80% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.31 (m, 5H), 4.48 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 3.45 (t, J = 6.6 Hz, 2H), 
2.16 (t, J = 7.2 Hz, 2H), 1.99 (s, 3H), 1.88 (m, 2H), 1.49 (m, 2H), 1.44 (s, 18H); 13C NMR 
(126 MHz, CDCl3) δ 171.0, 170.4, 138.6, 128.4, 127.7, 127.6, 81.6, 72.9, 70.3, 60.8, 
56.6, 30.6, 29.1, 27.9, 24.5, 21.0; IR (neat) cm-1 2975, 1720, 1367, 1235, 1147; HRMS 
(C25H38O7, ESI): calculated 473.2516 [M+Na]+1, found 473.2499. 
3.6.2 Synthesis of intermediate 79 
 
 
Figure 45. Intermediate 79 
 
 
 To a 25 mL round bottom flask, was added compound 83 (260 mg, 0.58 mmol) in 
MeOH (12 mL), followed by K2CO3 (160 mg, 1.2 mmol). The mixture was stirred at room 
temperature for 1 hour and then added to H2O (2 mL) and diluted with Ethyl acetate (5 
mL). HCl was added until the solution was neutralized. The layers were separated, and 
the aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined organic 
layers were dried with MgSO4, filtered and concentrated in vacuo. The resulting crude 
material did not need any further purification and was isolated as a colorless oil (206 mg, 
88% yield) which was used directly in the next step. To a 10 mL round bottom flask, was 
added the above alcohol (206 mg, 0.50 mmol) in dichloroethane (5 mL), followed by R-
TRIP 30b (38 mg, 0.050 mmol). The reaction was stirred at room temperature for 10 
days then diluted with CH2Cl2 (10 mL) and added H2O (5 mL). The layers were 
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separated, and the aqueous layer was extracted with ethyl acetate (3 x 5 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by silica gel column chromatography (20% to 30% ethyl 
acetate/hexanes) to afford 79 as a colorless oil (68 mg, 40% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.32 (m, 5H), 4.48 (s, 2H), 4.30 (m, 2H), 3.49 (m, 2H), 2.66 (m, 1H), 2.22 (m, 
1H), 2.11 (m, 1H), 1.82 (m, 1H), 1.74 (m, 1H), 1.56 (m, 1H), 1.45 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 175.3, 168.6, 138.4, 128.5, 127.8, 127.8, 83.1, 73.0, 69.9, 66.2, 54.6, 
31.9, 30.8, 27.9, 25.2; IR (neat) cm-1 2976, 2342, 1770, 1721, 1368; HRMS (C19H26O5, 
ESI) calculated 357.1678 [M+Na]+1, found 357.1661. 
3.6.3 Synthesis of compound 80 
 
 
Figure 46. Compound 80 
 
 
 To a 10 mL round bottom flask was added compound 79 (68 mg, 0.20 mmol) 
dissolved in CH2Cl2 (2 mL). Trifluoroacetic acid was added in excess (0.5 mL) and the 
reaction was left stirring for 1 hour. The mixture was then concentrated under vacuum to 
remove any residual trifluoroacetic acid and the product 80 was obtained without 
purification as a colorless oil (56 mg, 99% yield). 1H NMR (500 MHz, CDCl3) δ 10.27 (bs, 
1H), 7.32 (m, 5H), 4.51 (s, 2H), 4.35 (m, 2H), 3.52 (m, 2H), 2.74 (m, 1H), 2.25 (m, 1H), 
2.17 (m, 1H), 1.88 (m, 1H), 1.76 (m, 1H), 1.61 (m, 1H
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APPENDIX A 
 
NMR SPECTRA 
 
 
The 1H and 13C nuclear magnetic resonance (NMR) spectra were plotted on 400 and 
500 MHz spectrometer using CDCl3 as a solvent at room temperature. The NMR 
chemical shifts (δ) are reported in ppm. 
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APPENDIX B 
CHROMATOGRAMS 
HPLC chromatograms were obtained using an Agilent 1260 Infinity and Varian Prostar 
HPLC systems. 
The Agilent 1260 Infinity HPLC system is equipped with an Agilent 1260 autosampler, an 
Agilent 1260 quaternary pump, Agilent 1260 diode array detectors (DAD), and the data 
analysis software used was Agilent ChemStation. 
The Varien Prostar HPLC system is equipped with Prostar 210 pumps and a Prostar 335 
photodiode array detector (PDA), with the collection and analysis of data using Galaxie 
Chromatography Workstation software instrument. 
Analysis details can be found with each chromatogram.
74 
Compound 49- Racemic 
HPLC Conditions: Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 210 nm 
Compound 49- Enantioenriched 
HPLC Conditions: Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 210 nm 
DAD1 A, Sig=254,4 Ref=360,100 (EM2\KSP 2017-11-05 20-54-24\JEW-V-185.D) 
mAU 
45 
40 
35 
30 
25 
20 
15 
10 
5 
26 28 30 32 34 36 38 min
 ----|-------|---|----|----------|----------|---------|  
1 31.667 1 MF 3965.68652 40.27905 51.8111 
2 33.930 1 FM 3688.44409 34.82159 48.1889 
31
.6
6
7
 
33
.9
3
0
 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
mAU
70 
60 
50 
40 
30 
20 
10 
0 
26 28 30 32 34 36 38 min 
DAD1 A, Sig=254,4 Ref=360,100 (EM2\KSP 2017-11-05 22-23-27\KJS-II-293.D) 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
----|-------|---|----|----------|----------|--------|  
1 31.515 1 MF 7021.16748 78.45442 91.7572 
2 33.847 1 FM 630.73370 5.70773 8.2428 
31
.5
15
 
33
.8
47
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Compound 38- Racemic 
HPLC Conditions: Column: HPLC OD-RH; Eluent Rate: 1mL/min; Eluent: 40% 
Acetonitrile/Aqueous; Monitoring wave: 254 nm 
 
 
 
 
Compound 38- Enantioenriched (before recrystallization) 
HPLC Conditions: Column: HPLC OD-RH; Eluent Rate: 1mL/min; Eluent: 40% 
Acetonitrile/Aqueous; Monitoring wave: 254 nm 
 
 
DAD1 A, Sig=254,4 Ref=360,100 (EM2\KSP 2017-11-29 12-18-43\EM-II-59.D) 
 
mAU 
 
 
150 
 
125 
 
100 
 
75 
 
50 
 
25 
 
0 
 
5 6 7 8 9 min
 
 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
----|-------|---|----|----------|----------|--------|  
1 6.418 1 MF 2339.87256 181.26688 49.0767 
2 6.859 1 FM 2427.91797 170.05028 50.9233 
6
.4
18
 
6.
85
9
 
 
DAD1 A, Sig=254,4 Ref=360,100 (EM2\KSP 2017-11-29 13-42-21\EM-II-65_RIGHT ONE.D) 
 
mAU 
 
70 
 
60 
 
50 
 
40 
 
30 
 
20 
 
10 
 
0 
 
5 6 7 8 9 min
 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
----|-------|---|----|----------|----------|--------|  
1 6.393 1 MF 1059.39099 83.70535 79.9284 
2 6.836 1 FM 266.03412 18.34127 20.0716 
6
.3
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6
.8
3
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Compound 38- Enantioenriched (after recrystallization) 
HPLC Conditions: Column: HPLC OD-RH; Eluent Rate: 1mL/min; Eluent: 40% 
Acetonitrile/Aqueous; Monitoring wave: 254 nm 
 
 
 
Compound 53- Racemic 
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 210 nm 
 
 
DAD1 A, Sig=254,4 Ref=360,100 (EM2\KSP 2017-12-19 16-07-01\EM-II-65_RECRYST_DILUTED.D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
----|-------|---|----|----------|----------|--------|  
1 6.262 1 MF 2.47282e4 1838.97388 92.3033 
2 6.721 1 FM 2061.96826 122.31843 7.6967 
mAU 
1750 
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DAD1 B, Sig=210,4 Ref=360,100 (EM2\KSP 2018-06-17 14-57-22\EM-II-135_II.D) 
mAU 
300 
 
 
250 
 
 
200 
 
 
150 
 
 
100 
 
 
50 
 
 
0 
 
12.5 13 13.5 14 14.5 m
 
 
----|-------|---|----|----------|----------|--------|  
1 12.501 1 MM 6181.32471 317.76920 49.4518 
2 14.053 1 MM 6318.38184 271.24738 50.5482 
Peak Ret   Sig Type Area Height Area 
#    [min] [mAU*s] [mAU] % 
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01
 
14
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Compound 53- Enantioenriched  
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
Compound 41- Racemic 
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 254 nm   
 
DAD1 B, Sig=210,4 Ref=360,100 (EM2\KSP 2018-06-17 14-57-22\EM-II-133_II.D) 
mAU 
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60 
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12.5 13 13.5 14 14.5 min
 
 
 
 
----|-------|---|----|----------|----------|--------|  
1 12.580 1 MM 1140.13831 64.30721 29.8325 
2 14.152 1 MM 2681.65649 120.48559 70.1675 
Peak RetTime Sig Type Area Height Area 
# [min] [mAU*s] [mAU] % 
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Compound 41- Enantioenriched  
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 254 nm   
 
 
 
 
Compound 70- Racemic 
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 5% IPA/hexane; Monitoring wave: 254 nm 
 
DAD1 A, Sig=254,4 Ref=360,100 (WASHES\KSP 2018-09-18 11-28-05\EM-II-175_6-10.D) 
mAU 
6 
4 
2 
0 
-2 
18.5 19 19.5 20 20.5 21 21.5 min
Peak RetTime Sig Type  Area Height Area 
# [min] [mAU*s] [mAU]  % 
----|-------|---|----|----------|----------|--------|  
1 19.293 1 MM 218.52594 8.86356 62.8223 
2 21.339 1 MM 129.32158 4.98933 37.1777 
1
9
.2
9
3
 
2
1
.3
3
9
 
                      
1
7
. 
                   
1
9
.4
5 
8
7
 racemic lactone13_22_2019 8_34_02 PM.DATA - PS 335 Channel 2 
16 
14 
12 
10 
8 
6 
4 
2 
0 
16 16.216.416.616.8 17 17.217.417.617.8 18 18.218.418.618.8 19 19.219.419.619.8 20 20.220.420.620.8 21 
Min 
Index Name Time 
[Min] 
Quantity 
[% Area] 
Height 
[mAU] 
Area 
[mAU.Min] 
Area % 
[%] 
1 UNKNOWN 17.87 49.91 15.2 6.4 49.913 
2 UNKNOWN 19.45 50.09 13.6 6.4 50.087 
       
Total   100.00 28.8 12.7 100.000 
m
A
U
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Compound 70- Enantioenriched 
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 5% IPA/hexane; Monitoring wave: 254 nm 
 
 
 
 
Compound 40 - Racemic 
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 220 nm 
 
 
5
2
 
17
. 
Chiral lactone 3_22_2019 7_10_51 PM.DATA - PS 335 Channel 2 
50 
40 
30 
20 
10 
0 
1616.16.126.136.146.156.166.176.186.91717.17.127.137.147.157.167.177.187.91818.18.128.138.148.158.168.178.188.91919.19.129.139.149.159.169.179.189.920 
Min 
Index Name Time 
[Min] 
Quantity 
[% Area] 
Height 
[mAU] 
Area 
[mAU.Min] 
Area % 
[%] 
1 UNKNOWN 17.52 87.77 55.8 23.4 87.771 
2 UNKNOWN 19.13 12.23 7.3 3.3 12.229 
       
Total   100.00 63.0 26.6 100.000 
m
A
U
 
1
9
.1
3
 
Racemicspiro6 3_24_2019 6_39_08 PM.DATA - PS 335 Channel 2 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
24 24.224.424.624.8 25 25.225.425.625.8 26 26.226.426.626.8 27 27.227.427.627.8 28 28.228.428.628.8 29 
Min 
 
 
Index Name Time 
[Min] 
Quantity 
[% Area] 
Height 
[mAU] 
Area 
[mAU.Min] 
Area % 
[%] 
1 UNKNOWN 25.09 49.83 65.8 46.2 49.831 
2 UNKNOWN 27.85 50.17 67.1 46.5 50.169 
       
Total   100.00 132.9 92.6 100.000 
 
            
25
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9 
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Compound 40- Enantioenriched  
HPLC Conditions: Column: HPLC AD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 10% IPA/hexane; Monitoring wave: 220 nm 
 
 
 
          
24
. 
                            
2
7
.4
0
 
8
8
 Enantioenrichspiro1 3_24_2019 6_02_20 PM.DATA - PS 335 Channel 1 
400 
350 
300 
250 
200 
150 
100 
50 
0 
24 24.224.424.624.8 25 25.225.425.625.8 26 26.226.426.626.8 27 27.227.427.627.8 28 28.228.428.628.8 29 
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Index Name Time 
[Min] 
Quantity 
[% Area] 
Height 
[mAU] 
Area 
[mAU.Min] 
Area % 
[%] 
1 UNKNOWN 24.88 85.99 375.1 214.6 85.993 
2 UNKNOWN 27.40 14.01 61.0 35.0 14.007 
       
Total   100.00 436.1 249.6 100.000 
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